Malária no município de Humaitá, estado do Amazonas: XXI. Prevalência da deficiência de glicose-6-fosfato desidrogenase (G6PD) Em amostra da população e em doentes com malaria causada pelo Plasmodium falciparum

Barraviera, Benedito; Meira, Domingos Alves; Machado, Paulo Eduardo de Abreu; Curi, P. R.

doi:10.1590/s0036-46651987000600007

Cited by 7 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a traditionally malaria-endemic area of South-eastern Brazil, the frequency of G6PDd and average G6PD activity was similar between the groups with and without a history of malaria [106]. Plasmodium falciparum infections were recorded at the same proportion in G6PDd and normal individuals in the Southern Brazilian Amazon [107]. In Brazil, an absence of association between G6PD phenotypes and the number of previous episodes of malaria in men was reported [108].…”

Section: Resultsmentioning

confidence: 99%

Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes

Monteiro

Franca

Queiroz

et al. 2014

Malar J

View full text Add to dashboard Cite

BackgroundAlthough G6PDd individuals are generally asymptomatic throughout their life, the clinical burden of this genetic condition includes a range of haematological conditions, including acute haemolytic anaemia (AHA), neonatal jaundice (NNJ) and chronic non-sphaerocytic anaemia (CNSA). In Latin America (LA), the huge knowledge gap regarding G6PDd is related to the scarce understanding of the burden of clinical manifestation underlying G6PDd carriage. The aim of this work was to study the clinical significance of G6PDd in LA and the Caribbean region through a systematic review.MethodsA systematic search of the published literature was undertaken in August 2013. Bibliographies of manuscripts were also searched and additional references were identified. Only original research was included. All study designs were included, as long as any clinical information was present. Studies were eligible for inclusion if they reported clinical information from populations living in LA or Caribbean countries or about migrants from these countries living in countries outside this continent.ResultsThe Medline search generated 487 papers, and the LILACS search identified 140 papers. After applying the inclusion criteria, 100 original papers with any clinical information on G6PDd in LA were retrieved. Additionally, 16 articles were included after reading the references from these papers. These 116 articles reported data from 18 LA and Caribbean countries. The major clinical manifestations reported from LA countries were those related to AHA, namely drug-induced haemolysis. Most of the published works regarding drug-induced haemolysis in LA referred to haemolytic crises in P. vivax malaria patients during the course of the treatment with primaquine (PQ). Favism, infection-induced haemolysis, NNJ and CNSA appear to play only a minor public health role in this continent.ConclusionHaemolysis in patients using PQ seems to be the major clinical manifestation of G6PDd in LA and contributes to the morbidity of P. vivax infection in this continent, although the low number of reported cases, which could be linked to under-reporting of complications. These results support the need for better strategies to diagnose and manage G6PDd in malaria field conditions. Additionally, Malaria Control Programmes in LA should not overlook this condition in their national guidelines.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes

Monteiro

Franca

Queiroz

et al. 2014

Malar J

View full text Add to dashboard Cite

show abstract

“…It can manifest as homozygous or heterozygous inheritance in females and hemizigous in males [ 23 ]. In heterozygous females normal red blood cells can coexist with red blood cells deficient in G6PD, in variable proportion [ 7 ], and this can cause a milder hemolytic anemia when exposed to primaquine. At the same time, there are 180 different genetic variants of G6PD, resulting in different levels of hemolysis [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

“…Primaquine is the only antimalarial drug with effective activity against all the species gametocytes of Plasmodium which cause malaria in humans, as well as against hypnozoites, latent forms of P. vivax and P. ovale responsible for relapses [ 7 ]. However, it has hemolytic effects, especially in people with glucose-6-phosphate dehydrogenase deficiency (G6PD), in which primaquine as a stressor to the erythrocyte induces hemolysis.…”

Section: Introductionmentioning

confidence: 99%

Side Effects of Chloroquine and Primaquine and Symptom Reduction in Malaria Endemic Area (Mâncio Lima, Acre, Brazil)

Braga

Martins

Cayotopa

et al. 2015

Interdisciplinary Perspectives on Infectious Diseases

View full text Add to dashboard Cite

Side effects of antimalarial drug can overlap with malaria symptoms. We evaluated 50 patients with vivax malaria in Mâncio Lima, Acre, treated with chloroquine and primaquine. Patients were evaluated for the presence of 21 symptoms before and after treatment and for reported side effects of these drugs after treatment was started. The most frequent symptoms before medication were headache, fever, chills, sweating, arthralgia, back pain, and weakness, which were present in between 40% and 76% of respondents. The treatment reduced the occurrence of these symptoms and reduced the lack of appetite, but gastrointestinal symptoms and choluria increased in frequency. There were no reports of pale stools before medication, but 12% reported the occurrence of this symptom after treatment started. Other symptoms such as blurred vision (54%), pruritus (22%), paresthesia (6%), insomnia (46%), and “stings” into the skin (22%) were reported after chloroquine was taken. The antimalarial drugs used to treat P. vivax malaria reduce much of the systemic and algic symptoms but cause mainly gastrointestinal side effects that may lead to lack of adherence to drug treatment. It is important to guide the patient for the appearance and the transience of such side effects in order to avoid abandoning treatment.

show abstract

“…( 15 - 17 ) Other studies evaluating population prevalence for G6PD deficiency in Brazil among adults and children obtained a mean prevalence of 3.59%, varying between 1.70 and 4.96% of G6PD-deficient subjects. ( 18 - 26 )…”

Section: Discussionmentioning

confidence: 99%

Prevalence of G6PD deficiency and molecular characterization of G202A, A376G and C563T polymorphisms in newborns in Southeastern Brazil

Pereira¹,

Bravin²,

Cintra³

et al. 2019

Einstein (São Paulo)

View full text Add to dashboard Cite

Objective To evaluate the prevalence of G6PD deficiency and characterize G202A, A376G and C563T polymorphisms in neonates using molecular assays. Methods A total of one thousand samples were tested through quantitative analysis of enzyme activity, detecting 25 G6PD-deficient individuals. Patients identified as deficient were submitted to molecular analysis quantitative real-time polymerase chain reaction – (qPCR) to investigate the presence of variants associated with the deficiency. Results The total prevalence of G6PD deficient was 2.5%. Of the 25 samples identified as deficient, 21 were submitted to qPCR assay to analyze the presence of G202A, A376G and C563T variants. All samples showed the G202A/A376G genotype, characterizing G6PD A- phenotype. Conclusion The prevalence of G6PD deficiency in the present study was similar to that observed in other study populations in Brazil. Molecular analysis identified in all patients the presence of the genetic polymorphism G202A/A376G, more common in the Brazilian population with G6PD deficiency, which is directly estimated by enzyme activity level.

show abstract

Malária no município de Humaitá, estado do Amazonas: XXI. Prevalência da deficiência de glicose-6-fosfato desidrogenase (G6PD) Em amostra da população e em doentes com malaria causada pelo Plasmodium falciparum

Abstract: BESÜMOOs autores estudaram a prevalência da deficiência de glicose-6-fosfato desi.' drogenase (G6PD), peto método de BREWER, et alii, em 141 UNITERMOS: Malária; Glicose-G-fosfato desidrogenase (G6PD); Plasmodium fal, ciparum.

Cited by 7 publications

References 13 publications

Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes

Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes

Side Effects of Chloroquine and Primaquine and Symptom Reduction in Malaria Endemic Area (Mâncio Lima, Acre, Brazil)

Prevalence of G6PD deficiency and molecular characterization of G202A, A376G and C563T polymorphisms in newborns in Southeastern Brazil

Contact Info

Product

Resources

About